Special Issue "Establishment and Characterization of Novel Patient-Derived Cancer Cell Line"

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: 31 March 2022.

Special Issue Editors

Dr. Yuki Yoshimatsu
E-Mail Website
Guest Editor
Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
Interests: paient-derived cancer model; rare cancer research; sarcoma; expanded indication; biobank; viral carcinogenesis; transcriptomics; exosome/miRNA; tissue culture; primary culture
Dr. Tadashi Kondo
E-Mail Website
Guest Editor
Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
Interests: rare cancer research; sarcoma; biobank; precision medicine; biomarker development; target discovery; patient-derived cancer model; proteogenomics; proteomics; bioinformatics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Patient-derived cancer cell lines have facilitated fundamental progress in cancer biology and revolutionized medicine. They enable functional studies of novel genes and proteins, allow the evaluation of anti-tumor effects of novel anti-cancer agents in a high-throughput manner, and provide insights into molecular mechanisms underlying the malignant behavior of cancer cells. The advent of genomics has identified a large number of intriguing genes, and such cell lines are required to interpret their functional properties and the significance of their aberrant regulation in the clinical tumors. The utility of cell lines has been widely recognized, and they have been deposited in cell banks to be shared with the research community. Although cell lines are important tools in cancer research, several critical issues remain to be addressed to improve their utility and possible applications. For example, according to cell line databases, such as Cellosaurus, only a limited number of cell lines have been established for any given cancer; moreover, for a considerable number of cancers, especially rare cancers, no cell lines have been established. Considering the heterogeneity of tumor tissues and the tissue-independence of gene function, we need to expand the collection of cell lines and share them with the research community.

The Special Issue will highlight the establishment and characterization of novel cell lines using clinical materials. Original contributions related to novel cell lines, characterization of novel and existing cell lines, technical notes for cell line establishment and application, and review articles of relevant topics are invited for publication in this Special Issue.

Dr. Yuki Yoshimatsu
Dr. Tadashi Kondo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Patient-derived cancer model
  • Cell line
  • Primary culture
  • Precision medicine
  • Therapeutic target
  • Biomarker

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Establishment and Characterization of NCC-DDLPS4-C1: A Novel Patient-Derived Cell Line of Dedifferentiated Liposarcoma
J. Pers. Med. 2021, 11(11), 1075; https://doi.org/10.3390/jpm11111075 - 24 Oct 2021
Viewed by 381
Abstract
Dedifferentiated liposarcoma (DDLPS) is a highly malignant sarcoma characterized by the co-amplification of MDM2 and CDK4. Although systemic chemotherapy is recommended for unresectable or metastatic cases, DDLPS is insensitive to conventional chemotherapy, leading to an unfavorable prognosis. Therefore, novel treatment methods are [...] Read more.
Dedifferentiated liposarcoma (DDLPS) is a highly malignant sarcoma characterized by the co-amplification of MDM2 and CDK4. Although systemic chemotherapy is recommended for unresectable or metastatic cases, DDLPS is insensitive to conventional chemotherapy, leading to an unfavorable prognosis. Therefore, novel treatment methods are urgently required. Patient-derived cell lines are essential in preclinical studies. Recently, large-scale screening studies using a number of cell lines have been actively conducted for the development of new therapeutic drugs. However, the DDLPS cell line cannot be obtained from public cell banks owing to its rarity, hindering screening studies. As such, novel DDLPS cell lines need to be established. Accordingly, this study aimed to establish a novel DDLPS cell line from surgical specimens. The cell line was named NCC-DDLPS4-C1. NCC-DDLPS4-C1 cells retained copy number alterations corresponding to the original tumors. Further, the cells demonstrated constant growth, spheroid formation, and equivalent invasiveness to MG63 osteosarcoma cells. We also conducted drug screening and integrated the results with those of the previously reported DDLPS cell lines. Consequently, we identified the histone deacetylase inhibitor romidepsin as a novel candidate drug. In conclusion, the NCC-DDLPS4-C1 cell line is a useful tool for the basic study of DDLPS. Full article
Show Figures

Figure 1

Back to TopTop